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C-jun N-terminal kinase (JNK) regulates both the
development of insulin resistance and inflammation.
Podocytes of the widely used db/db mouse model of diabetic
nephropathy lose their ability to respond to insulin as
albuminuria develops, in comparison to control db/þ mice.
Here we tested whether JNK inhibition or its gene deletion
would prevent albuminuria in experimental diabetes.
Phosphorylated/total JNK was significantly increased in vivo
in glomeruli of db/db compared to db/þ mice. Treatment of
podocytes isolated from these two strains of mice with tumor
necrosis factor-a caused greater phosphorylation of JNK in
those obtained from diabetic animals. When db/db mice
were treated with a cell-permeable TAT-JNK inhibitor
peptide, their insulin sensitivity and glycemia significantly
improved compared to controls. We induced diabetes in
JNK1 knockout mice with streptozotocin and found that they
had significantly better insulin sensitivity compared to
diabetic wild-type or JNK2 knockout mice. Albuminuria was,
however, worse in all mice treated with the JNK inhibitor and
in diabetic JNK2 knockout mice compared to controls.
Nephrin expression was also reduced in JNK inhibitor-treated
mice compared to controls. A similar degree of mesangial
expansion was found in all diabetic mice. Our study shows
that targeting JNK to improve systemic insulin sensitivity
does not necessarily prevent diabetic nephropathy.
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Diabetic nephropathy (DN) is the leading cause of end-stage
renal disease,1 and microalbuminuria is an independent
predictor of cardiovascular disease and of progression to end-
stage renal disease.2–4 In diabetes, inflammation and
inflammatory cytokines are implicated in the pathogenesis
of insulin resistance and DN.5–8 A role for insulin resistance
in DN has been suggested,9,10 and a recent study showed
that glucose disposal rate in type 2 diabetic patients was
inversely associated with an increased prevalence of micro-
albuminuria.11
Several intracellular mediators of inflammatory stress have
been identified. Among them, c-jun N-terminal kinase (JNK)
is a key player of inflammatory stress and cell death in several
chronic inflammatory diseases.12,13 Furthermore, JNK is
activated in peripheral tissues of experimental model of
diabetes mellitus, where it suppresses insulin receptor
signaling mainly through insulin receptor substrate phos-
phorylation at different serine and threonine sites.14,15 In
addition, we have recently shown that JNK inhibition may
improve human pancreatic-b cell function and viability via
restoration of local insulin signaling.16 JNK1 is the JNK
isoform primarily involved in insulin sensitivity,15 although
JNK2 can affect insulin signaling as well.17
Podocytes, the glomerular cells responsible for the initial
development of microalbuminuria, have been reported to be
a target for insulin. Podocytes express all the elements of the
insulin signaling cascade and are able to uptake glucose in
response to insulin.18 We have recently shown that podocytes
from a widely used animal model of DN (db/db) lose their
ability to respond to insulin compared to control at the time
of development of albuminuria.19 This inability to respond to
insulin resulted in a decreased ability to phosphorylate AKT
and in an increased susceptibility to cell death.
Several studies have suggested a crosstalk between JNK
and AKT.20 In freshly isolated human islets, inhibition of
AKT was shown to result in a time dependent increase in JNK
activity, which in turn resulted in an increased islet apoptosis.
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Similarly, we have shown that inhibition of JNK resulted in an
increased AKT activity in human islets exposed to cytokines.16
This suggests that JNK is a key regulator of AKT signaling
pathway and that inhibition of JNK might improve insulin
signaling and the podocyte response to injury.
In the current study we hypothesize that glomerular JNK
is upregulated in early experimental DN, and that inhibition
of JNK prevents the development of albuminuria. We found
that the absence of either JNK isoforms or JNK inhibition
with a cell permeable peptide (JNKi) improve systemic
insulin sensitivity but fail to prevent albuminuria. Our study
strongly suggests that JNK as a means to improve systemic
insulin sensitivity does not necessarily translate into the
prevention of DN.
RESULTS
Glomerular JNK phosphorylation is higher in db/db than in
db/þ mice
We analyzed phosphorylated and total JNK on microdis-
sected glomeruli by Luminex technology. Glomeruli from
db/db mice had higher phosphorylated/total JNK as com-
pared to db/þ (0.6±0.05 vs 0.4±0.08, respectively, Po0.05;
Figure 1a). JNK phosphorylation did not differ at baseline
between db/db and db/þ podocytes (0.22±0.36 vs
0.14±0.23, P¼NS). However, exposure to serum starvation
alone or tumor necrosis factor-a (TNF-a) (2000 U/ml) led to
a significant upregulation of phosphorylated JNK in
podocytes from db/db but not db/þ mice (Figure 1b).
Interestingly, addition of serum starvation in combination
with TNF-a did not have an additive effect on JNK
phosphorylation.
JNKi-treated db/db mice and diabetic JNK1/ have better
glycemia and insulin sensitivity when compared to control
mice
We utilized a cell permeable TAT-JNK inhibitor peptide
(JNKi) and a TAT-scrumble peptide (TAT) that we have
previously described.16 After a 10-week course of treatment
with JNKi, db/db mice had a significant improvement in
their random glycemia when compared to TAT-treated mice
(248±122 vs 413±142 mg/100 ml, Po0.05; Figure 2a). This
was attributed to improved insulin sensitivity, because insulin
injection after an overnight fast led to a faster return to
normoglycemia in db/db mice treated with JNK inhibitor
when compared to scramble peptide (Po0.05; Figure 2b). To
further characterize the role of JNK in the development of
DN, we studied JNK1/ and JNK2/ rendered diabetic
after streptozotocin (STZ) administration. Glycemia was
identical in diabetic WT, JNK1/, and JNK2/ mice
(Figure 2c). Insulin sensitivity in diabetic JNK1/mice was
improved as compared to control and JNK2/ (Po0.05;
Figure 2d). Glucose tolerance tests were equal among groups
at baseline (data not shown).
JNKi is functional in glomeruli but has no effect on AKT and
downregulates nephrin expression
To verify if treatment with JNKi was effective in glomeruli, we
compared the phosphorylated/total c-jun expression in
glomeruli of db/db vs db/þ mice injected with either TAT
or JNKi. A significant downregulation of c-jun phosphoryla-
tion was observed in mice treated with JNKi (Figure 3a).
Despite effective pharmacological inhibition of c-jun phos-
phorylation, JNKi failed to upregulate the phosphorylation of
AKT (Figure 3b). As nephrin has been shown to phosphor-
ylate AKT,21 we also measured nephrin mRNA expression in
glomeruli from db/db and db/þ mice at 18 weeks of age. We
found that nephrin expression was reduced in db/db
glomeruli when compared to db/þ and was further down-
regulated by treatment with JNKi (Po0.01; Figure 3c).
Cultured podocytes exposed to JNKi also failed to upregulate
AKT phosphorylation (Figure 3d).
JNKi did not prevent cell death under condition of stress
We have previously shown that db/db podocytes are more
susceptible to cell death after exposure to inflammatory
stimuli though as dysregulation of AKT.19 As we found a
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Figure 1 | JNK is phosphorylated in glomeruli and podocytes
from diabetic mice. (a) Phosphorylated/total JNK in glomeruli
from db/þ (white bar) and db/db mice (black bar) showing
higher phosphorylated/total JNK in db/db compared to db/þ .
*Po0.05. (b) Phosphorylated/total JNK in db/þ (white bars) or
db/db (black bars) podocytes either untreated (Control) or
exposed to serum starvation (0.1% FBS), TNF, or a combination of
serum starvation and TNF-a at a dose of 2000 U/ml
(0.1%FBSþ TNF). Data are expressed as percentage of control to
account for interassay variability. *Po0.05 or **Po0.01 when
comparing treated db/db podocytes to controls.
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Figure 2 | JNKi and JNK gene knockout affects insulin sensitivity in two different experimental models of diabetes. (a) JNKi treatment
in db/db mice (gray bar) led to a reduction in random glycemia (mg/100 ml) compared to TAT (black bar). *Po0.05. (b) Glycemia was
evaluated before and after intraperitoneal injection of short-acting insulin (2 mU/g body weight). Insulin sensitivity is expressed as
percentage glycemia at time 60 min compared to time 0. Insulin sensitivity was improved in JNKi-treated db/db mice compared to TAT-
treated mice. *Po0.05. (c) JNK1/ D and JNK2/ D mice (gray bars) did not have better random glycemia (mg/100 ml) as compared to
WT D (white bar). (d) Insulin sensitivity, measured as described in (b), was better in JNK1/ D (gray bar) as compared to WT D (white bar)
and JNK2/ D (gray bar). *Po0.05 when comparing JNK1/ D to both WT D and JNK2/ D.
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Figure 3 | JNKi effectively inhibits glomerular c-jun but has no effect on AKT and negatively affects nephrin expression. (a) JNKi
treatment decreases phosphorylated/total c-jun (gray bars) in glomeruli of both db/þ and db/db as compared to TAT-treated mice.
*Po0.05, **Po0.01. (b) JNKi treatment did not affect phosphorylated/total AKT in both db/þ and db/db glomeruli (gray bars) as compared
to TAT-treated mice. (c) db/db glomeruli (black bar) have decreased nephrin mRNA expression compared to db/þ (white bar).
^^Po0.01. Treatment with JNKi (gray bars) resulted in a downregulation of nephrin mRNA in both db/þ and db/db glomeruli, **Po0.01,
***Po0.001. (d) JNKi treatment did not affect phosphorylated/total AKT in both db/þ and db/db podocytes (gray bars) as compared to
TAT-treated cells.
Kidney International (2009) 75, 381–388 383
A Ijaz et al.: Insulin resistance and diabetic nephropathy o r i g i n a l a r t i c l e
profound upregulation of JNK by such stimuli (Figure 1a),
and JNK and AKT are inversely related,16 we tested if
inhibition of JNK in vitro could prevent cell death in diabetic
podocytes. We utilized podocytes isolated from 12 weeks old
mice, an age when no differences in glomerular nephrin
mRNA expression were observed in our previous study.19
JNK inhibition did not prevent podocyte cell death
(Figure 4) and failed to upregulate AKT (data not shown),
consistent with the results obtained on microdissected
glomeruli.
JNKi or JNK gene knockout does not prevent albuminuria
Albuminuria (albumin/creatinine ratio) was not different
between TAT- or JNKi-treated db/þ mice (26.31±18.54 vs
16.46±8.21 mg/mg). However, JNKi treatment was deleter-
ious in db/db mice and resulted in significant worsening of
albuminuria (106.9±26.4 vs 131.1±55.60mg/mg in TAT vs
JNKi, respectively) at killing (Figure 5a). In a second model
of STZ-induced diabetes, diabetic wild-type mice (WT D)
had significantly greater albuminuria than WT controls
(31.8±15.6 vs 6.3±2.2 mg/mg, Po0.01). Albuminuria was
not improved in diabetic JNK1/ mice when compared to
diabetic WT (31.7±15.4 vs 31.8 ±15.6 mg/mg). However,
diabetic JNK2/ mice had significantly worse albuminuria
than diabetic WT (85.9±10.1 vs 31.8±15.6 mg/mg,
Po0.001; Figure 5b). No significant difference in albumi-
nuria was detected at earlier time points. WT, JNK1/ and
JNK2/ diabetic mice had higher kidney/body weight
ratios when compared to WT controls (Table 1).
JNKi or JNK gene knockout does not prevent mesangial
expansion
We analyzed the degree of mesangial expansion in Periodic
acid-Shiff stained kidney sections at killing. Glomeruli from
db/db mice had worse mesangial expansion as compared to
db/þ (2.5±0.6 vs 1.1±0.4, Po0.05 Figure 6a, c, and e).
However, JNKi did not prevent mesangial expansion in db/db
mice (2.9±0.5 vs 2.5±0., Figure 6c–e). Similarly WT diabetic
developed significant mesangial expansion at 18 weeks of age
(1.69±0.68 vs 0.50±0.20, Po0.05, Figure 6g, f and j).
However, there was no significant difference in the degree of
mesangial expansion among JNK1/, JNK2/, or WT D
mice (Figure 5g–j).
DISCUSSION
Ample clinical and experimental evidence have established a
link between insulin resistance and development of albumi-
nuria.9–11 Similarly, the basal insulin signaling is compro-
mised in the retina of rats with STZ-induced diabetes.22
Furthermore, renal disease similar to DN can be observed in
patients with a genetic mutation of insulin receptor, which
would again suggest disruption of normal insulin signaling as
part of the disease process in DN.23 The DCCT and UKPDS
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Figure 4 | JNKi does not affect podocyte cell death. The
percentage of 7-amino-actinomycin-D (7AAD) positive cells was
analyzed by flow cytometry in db/þ (white bars) and db/db
(black bars) podocytes exposed to a combination of serum
starvation and TNF-a at a dose of 2000 U/ml (TNF). TNF led to a
significant increase in cell death in both db/þ and db/db
podocytes. Addition of JNKi to TNF-treated cells (TNFþ JNKi, gray
bars) did not lead to significant decrease in cell death in either cell
type when compared to TNF-treated cells. *Po0.05 when
comparing TNF-treated db/þ to untreated cells (CTRL),
***Po0.001 when comparing TNF-treated db/db to untreated
cells (CTRL).
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Figure 5 | JNKi or JNK gene knockout does not prevent
albuminuria. (a) Comparison of albumin/creatinine ratio (mg/mg)
between TAT- and JNKi-treated db/þ and db/db mice showing
worsening of albuminuria in JNKi-treated db/db mice. *Po0.05
when comparing db/db JNKi to db/db TAT. (b) Comparison of
albumin/creatinine ratio (mg/mg) between wild-type nondiabetic
(WT ND), WT diabetic (WT D), JNK1/ D and JNK2/ D.
Although WT D mice developed significant albuminuria when
compared to WT ND at 12 weeks after induction of diabetes
(**Po0.01), JNK2/ D developed worse albuminuria when
compared to both JNK1/ D and WT D (***Po0.001).
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trials have clearly established a link between glycemic control
and development of albuminuria.24,25 Very few studies,
however, have compared if insulin sensitizer are superior to
other hypoglycemic agents in achieving a greater reduction of
albuminuria for equal metabolic control in humans26,27 as
well as experimental diabetes.28 Given the recent concerns
developed in regard to the safety profile of rosiglitazone,29 we
have elected to utilize JNK inhibition as a novel mean to
improve insulin sensitivity to assess if the development of
MA could be prevented in experimental diabetes.
Our data that glomerular JNK phosphorylation in
increased in diabetic db/db mice (Figure 1a) are consistent
with a recent report on kidney sections of diabetic patients
with DN.30 JNK phosphorylation was also increased in
cultured podocytes exposed to inflammatory stress (Figure
1b), suggesting that JNK may be the mediator of the
increased podocyte susceptibility to cell death as we have
recently demonstrated in db/db podocytes in vitro 19 and
others have demonstrated in db/db podocytes in vivo.31 We
did not observe an additive effect of serum starvation and
TNF-a on JNK phosphorylation, indicating that JNK
activation was already maximal with serum starvation and/
or that the effect of TNF-a may have been masked by serum
starvation. To establish the importance of JNK activation in
the development of albuminuria in the early phases of DN,
we treated db/db and db/þ mice with JNKi before the onset
of microalbuminuria, which on the B57BL/6 background
develops at 12 weeks of age.19 We utilized protein
transduction domain technology, which we have shown to
be effective for in vivo protein delivery to kidney cortex in
previous studies.16 We observed an expected improvement of
diabetes (Figure 2a and b), consistent to what have been
shown with JNK gene knockout,15 and utilization of JNK
inhibitors.13 As insulin resistance has also been described in
type 1 diabetes,32,33 although it does not seem to correlate to
development of albuminuria,34 we also utilized a model of
STZ-induced diabetes in JNK1/ and JNK2/ mice.
Although we observed an improved insulin sensitivity in
JNK1/ diabetic mice when compared to WT mice,
JNK2/ did not show any difference from WT (Figure
2d). This was expected, because JNK1 only plays a major role
in insulin sensitivity.15
Although JNK inhibitor was able to induce a significant
downregulation of c-jun in both db/þ and db/db glomeruli
(Figure 3a), an improvement of AKT phosphorylation was
not observed (Figure 3b), suggesting that other mechanisms
may be involved. It is remarkable to note that we did not
detect a significant difference in db/þ and db/db baseline
c-jun phosphorylation, which is in contrast to the different
degree of JNK phosphorylation shown in Figure 1a. However,
other kinases may have lead to a JNK-independent c-jun
regulation, as shown in other models.35,36 Recently, nephrin
has been shown to regulate AKT21 and to be essential for
insulin signaling in podocytes.37 As a downregulation of
nephrin could have explained the inability of JNK inhibitor
to regulate AKT in our model and could have explained the
worsening of albuminuria, we tested glomerular nephrin
mRNA expression. Although in our previous study we did
not find a significant difference in nephrin expression at 12
weeks of age,19 glomerular nephrin (Figure 3c), Expression
was lower in db/db mice when compared to db/þ by 18
weeks of age (Figure 3c). JNKi in vivo decreased nephrin
expression in both db/þ and db/db glomeruli. Whether such
downregulation of nephrin is responsible for the lack of
activity of JNK inhibitor on AKT remains to be established.
However, JNKi in diabetic podocytes from 12-week-old mice
(a time point where nephrin expression is normal) also failed
to demonstrate that JNK inhibition affects AKT (Figure 3d)
or prevent podocytes cell death (Figure 4). One alternative
possibility is that the sites responsible for podocyte-specific
insulin resistance are not the traditional sites affected by JNK
inhibitors such as the Ser 307 residue of insulin receptor
substrate-1.13 In fact, our previous observations had
suggested that a disruption of insulin receptor signaling
may occur even upstream of insulin receptor substrate-1/2,
because a downregulation of insulin receptor-b subunit was
also observed in diabetic podocytes.19 Thus, the identifica-
tion of therapeutic strategies to maintain a proper expression
and activity of insulin receptor per se is also needed.
Such inability to restore insulin signaling by JNK inhibitor
in vivo and in vitro was accompanied by a lack of prevention
of microalbuminuria in diabetic mice (Figure 5a). Similarly,
diabetic JNK1/ mice (which had a better insulin
sensitivity as shown in Figure 2d) had equal albumin/
creatinine ratio when compared to diabetic WT mice (Figure
5b). A significantly higher albuminuria was observed in
diabetic JNK2/ mice at killing (Figure 5b). Although we
did not identify the mechanism for increased albuminuria in
JNK2/ mice, this group of diabetic animals showed a
trend to increased kidney to body weight ratio when
compared to wild-type diabetics (Table 1), suggesting that
glomerular hypertrophy may be the potential mechanism
involved. It would be interesting to know if restoration of
JNK2 expression in diabetic JNK2/ may reverse albumi-
Table 1 | Kidney weight (mg), body weight (g) and kidney/body weight ratios (mg/g) in all animal models tested
WT WT D JNK1/D JNK2/ D db/+ TAT db/+ JNKi db/db TAT db/db JNKi
Kidney weight (mg) 218.2±46.3 256.7±25.1 247.3±72.6 330±37.9 166.7±15.2 169.5±15 256.7±46.1 263.5±27.8
Body weight (g) 25.8±0.7 20.2±1.2 17.75±1.1 22.17±2.1 21.33±1.0 21.99±1.6 53.5±3.1 49.82±3.2
Ratio (mg/g) 8.45±1.7 12.73±0.5* 13.93±3.2*** 17.14±4.6*** 7.81±0.6 7.71±0.4 4.80±0.7 5.29±0.7
JNK, c-jun N-terminal kinase; WT D, diabetic wild-type mice.
The kidney to body weight ratios of JNK1/ D and JNK2/ D were significantly higher than WT. ***Po0.001 when comparing JNK1/ D and JNK2/ D to WT.
*Po0.05 when comparing WT D to WT.
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nuria. The degree of mesangial expansion was also not
significantly different between JNKi- or TAT-treated mice
(Figure 6a–e) or in either JNK1/ or JNK2/ diabetic
mice when compared to diabetic WT.
In summary, we have demonstrated that glomerular JNK
is activated in the db/db model of DN. However, lack of
specific JNK isoforms or utilization of a pharmacologically
effective agent did not result in prevention of albuminuria
and mesangial expansion utilized as features of early DN.
This inability of JNK inhibitor to prevent early DN was
associated with improved glycemia and insulin sensitivity.
Thus, although a strong association between insulin resis-
tance and microalbuminuria has been established, we have
provided evidence that therapeutic intervention that effec-
tively improve insulin sensitivity do not necessarily translate
into renal protection.
MATERIALS AND METHODS
Mice killing and experimental design
B6.Cg-mþ /þ Lepr db/Lepr db (db/db), B6.Cg-m þ /þ Lepr
db/þ (db/þ ), Mapk8tm1Flv/J homozygous (JNK1/), and
Mapk9tm1Flv/J homozygous (JNK2/) mice on a C57BL6/J
background were obtained from Jackson Laboratories (Bar Harbor,
ME, USA). Mice were backcrossed for 10 generations into C57Bl6/J
background. C57BL6/J wild-type mice served as control (WT) of
JNK1/ and JNK2/ mice. Six mice per group were utilized. All
animal procedures were conducted under protocols approved by the
Institutional Animal Care and Use Committee, in adherence to the
NIH Guide for the Care and use of Laboratory Animals. Animals
were housed in a virus-antigen-free facility. The chemical induction
of diabetes was done with intra peritoneal injection of STZ 60 mg/
kg, for 3 consecutive days. Glycemia was monitored daily from tail
blood sample using standard test strips and glucometer (Bayer,
Pittsburgh, PA, USA) and mice were considered diabetic after five
consecutive readings of blood glucose above 250 mg/100 ml. After
diabetes induction, body weight and glycemia were measured
biweekly and urine collected weekly for analysis. Upon killing the
kidneys were perfused in situ with 6 ml of phosphate-buffered saline
and weighed immediately after removal. Kidneys to body weight
ratios were obtained. The upper pole of the left kidney was collected
and digested with a 5% collagenase type-IV solution (Sigma, St
Louis, MO, USA) for 40 min at 37 1C. Glomerular microdissection
was performed at 4 1C in a buffered solution containing protease
inhibitors (Roche, Indianapolis, IN, USA) and phosphatase
inhibitors (Sigma). Portions of right kidney were embedded in
OCT and stored at 80 1C. The right kidney was then perfused
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Figure 6 | JNKi or JNK gene knockout does not prevent mesangial expansion. (a–d) Representative PAS-stained histological kidney
sections of db/þ TAT (a), db/þ JNKi (b), db/db TAT (c), db/db JNKi (d). (e) Semiquantitative analysis revealed worse mesangial expansion
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in situ with 4% paraformaldehyde, postfixed in the same solution for
12 h, and then paraffin embedded.
Assessment of kinases
For glomeruli, phosphorylated and total JNK, c-jun, and AKT
were measured in 500 microdissected glomeruli per mouse as
previously described.8 Briefly an immunoassay using laser flow
cytometry (BioPlex; Bio-Rad, Hercules, CA, USA) was used.
Glomeruli were collected in lysis buffer. After determination of
protein concentration (DC; Bio-Rad), endogenous protein
phopshorylation was determined with the Bioplex platform as
per manufacturer’s recommendations. A protein concentration of
0.5 g/ml was determined to be optimal based on preliminary
experiments with serial dilution of protein samples to insure
the linear relationship between protein concentration and fluores-
cence. Results are expressed as ratios of phosphorylated to
total protein. For assessment of phosphorylated and total JNK in
cells, 300,000 cells/well of six well plates were plated and exposed to
either 0.1% fetal bovine serum (FBS) or 0.1% FBSþTNF-a
(2000 U/ml) for 48 h. Thereafter, cells were washed with phos-
phate-buffered saline  1 and cell lysates collected in 200 ml of lysis
buffer (Bio-rad) and utilized for analysis as described above for
glomerular lysates.
Albumin to creatinine ratio
Urine samples were collected before the onset of diabetes and then at
1-week intervals as well as at the time of killing. Albumin excretion
was measured by enzyme-linked immunosorbent assay (Bethyl,
Houston, TX, USA), corrected for creatinine concentration in the
urine (Stanbio, San Antonio, TX, USA) and expressed as albumin/
creatinine ratio (mg/mg).
Insulin sensitivity test
For the insulin tolerance test, mice were fasted for 4 h, with free
access to water, and then injected intraperitoneally with 2 mU/g
body weight of short acting insulin. Blood glucose levels were
measured before, and 15, 30, and 60 min after insulin injection.
Insulin sensitivity in each mouse was expressed as (glycemia at
60 min/glycemia at 0 min)*100.
JNKi treatment in vivo
db/db mice were injected every day for 10 weeks (from 8–18 weeks
of age) with an intraperitoneal injection of JNKi (10 mg/kg) or TAT
at the same dose. Preliminary experiments were performed with a
TAT-FITC peptide (10 mg/kg) to establish TAT-peptide renal tissue
penetrance (data not shown).
Cell culture and assessment of cell viability
db/db and db/þ podocytes were grown, cultured, and characterized
as previously described.8 Briefly, cells were grown on fibronectin
coated dishes in DMEM/F12 supplemented with 10% FBS. Cells up
to passage 20 were utilized for experiments. For JNK inhibitor
protection experiments, podocytes were treated with a 10mM
concentration of JNKi for 30 min before serum starvation and
addition of TNF-a as previously described.8 Cells were then treated
for 48 h with either 10% FBS media or 0.1% FBS media and TNF-a
(2000 U/ml; Roche, Florence, SC, USA). Podocytes were trypsinized,
washed once with phosphate-buffered saline and stained with the
membrane exclusion dye 7-amino-actinomycin D (Invitrogen,
Carlsbad, CA, USA), as marker for cell death. Analysis was
performed by flow cytometry (FACSCalibur; BD, Franklin Lakes,
NJ, USA) and data expressed as percentage of controls.
Assessment of mesangial expansion
Slide sections were prepared from paraffin-embedded samples.
Periodic acid-Shiff ’s staining of 5-mm thick slides was performed
and 20 glomeruli per section analyzed for mesangial expansion by
semiquantitative analysis (scale 0–4) by two blinded independent
investigators.
Measurement of glomerular nephrin mRNA expression
RNA extraction from 500 glomeruli per mouse was performed with
the RNAeasy extraction kit (Qiagen, Valencia, CA, USA), 1 mg RNA
was reverse transcribed to obtain cDNA and PCR assays were
performed to measure nephrin and 18S ribosomal RNA expression
using the ABI Prism 7500 Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA). Relative expression was
determined by the difference in the Ct values (cycle number needed
to amplify) for the target genes and the 18S Ct values. Relative
quantification between different samples was determined as 2DDCt
(DDCt¼DCt affected sample – DCt unaffected sample).
Statistical analysis
Results represent the mean of 3–5 independent experiments
performed in duplicate or triplicate. Results are expressed as
mean±s.d. Results were compared using analysis of variance
(ANOVA). When ANOVA showed a statistically significant differ-
ence, a group-by-group comparison was performed using a t-test
with a Tukey’s correction for multiple comparisons. Statistical
significance was set at Po0.05.
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